tiprankstipranks
iX Biopharma Ltd. (SG:42C)
SGX:42C
Singapore Market

iX Biopharma Ltd. (42C) Income Statement

Compare
6 Followers

iX Biopharma Ltd. Income Statement

Last quarter (Q4 2021), iX Biopharma Ltd.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, iX Biopharma Ltd.'s net income was $―. See iX Biopharma Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 21Jun 20Jun 19Jun 18Jun 17
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ -382.00K$ -587.00K$ -529.00K$ -247.00K$ 2.24M
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ ―$ ―$ ―$ ―$ ―
EBITDA
$ -7.00M$ -9.21M$ -11.82M$ -13.58M$ -6.06M
Operating Income
$ -10.08M$ -11.04M$ -11.91M$ -14.45M$ -8.57M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -8.23M$ -10.50M$ -2.99M$ -15.09M$ -7.39M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

iX Biopharma Ltd. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis